Could Pretreatment Neutrophil/Lymphosit Ratio and Derived Neutrophil/Lymphosit Ratio Predict Overall Survival of Patients With Extensive Stage Small Cell Lung Cancer?

Abstract

Objectives: We designed this study to evaluate the prognostic significance of basal neutrophil / lymphocyte ratio (NLR), derived NLR (dNLR) and systemic immune inflammation index (SII) in patients with extensive stage (ES) SCLC treated with platinum-based combination regimen. Methods: This study was a hospital-based retrospective observational case-series study. 145 ES SCLC patients were included the study from Dr. Ersin Arslan Education and Research Hospital Departments of Medical Oncology and Radiation Oncology between the years of 2011-2018. Results: The median age of the patients was 61 (range 31-81) years and 131 (90.3%) patients were male. 144 (99,3 %) patients were treated with the platinum etoposide combination regimen and 134 patients (92,4 %) received cisplatin in combination. The median follow-up time was 10 months and 116 (80%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated, respectively, as 8 and 12 months. Patients in the low NLR and low dNLR scores had better overall survival than those with high NLR and high dNLR (14 versus 10 months respectively and p=0,01). Conclusion: This study showed that basal NLR and dNLR may have prognostic biological value in patients with ES SCLC treated with cisplatin + etoposide